Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) Director Raymond Debbane acquired 50,000 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were acquired at an average cost of $1.44 per share, with a total value of $72,000.00. Following the transaction, the director directly owned 1,704,186 shares in the company, valued at $2,454,027.84. The trade was a 3.02% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Raymond Debbane also recently made the following trade(s):
- On Friday, February 20th, Raymond Debbane bought 100,000 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $1.48 per share, for a total transaction of $148,000.00.
Lexicon Pharmaceuticals Stock Performance
Shares of NASDAQ LXRX opened at $1.51 on Tuesday. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47. The business's 50 day moving average is $1.30 and its two-hundred day moving average is $1.30. The company has a market cap of $548.84 million, a P/E ratio of -7.95 and a beta of 0.98. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $1.83.
Analyst Ratings Changes
LXRX has been the topic of several research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen downgraded Lexicon Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, November 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Lexicon Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $3.23.
Check Out Our Latest Research Report on LXRX
Institutional Trading of Lexicon Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Lexicon Pharmaceuticals by 7.6% during the third quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company's stock worth $12,855,000 after acquiring an additional 670,838 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Lexicon Pharmaceuticals by 25.9% in the 4th quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company's stock valued at $5,545,000 after purchasing an additional 991,073 shares in the last quarter. UBS Group AG grew its holdings in shares of Lexicon Pharmaceuticals by 752.1% in the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company's stock worth $3,458,000 after purchasing an additional 2,654,315 shares during the last quarter. Geode Capital Management LLC grew its stake in Lexicon Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 2,500,022 shares of the biopharmaceutical company's stock worth $2,876,000 after buying an additional 102,099 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in Lexicon Pharmaceuticals during the third quarter worth about $3,240,000. Institutional investors and hedge funds own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
